AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study

This article was originally published here

The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung

The post AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply